Breadcrumbs

Urogenital - oncology

Bladder

Protocol Administration at chemotherapy unit level Review date
Bladder intravesical BCG (OncoTICE)
Low September 2022
Bladder intravesical gemcitabine High September 2022
Bladder intravesical mitomycin High March 2020
Bladder intravesical mitomycin single dose post TURBT
High September 2022
Bladder/Urothelial adjuvant ddMVAC (dose dense methotrexate vinBLASTine DOXOrubicin cISplatin) Medium September 2020
Bladder/Urothelial fluorouracil and mitomycin chemoradiation

Medium 2,3 Day 1 Low Day 22

September 2022
Bladder/Urothelial locally advanced definitive cISplatin (weekly) chemoradiation Medium March 2020
Bladder/Urothelial locally advanced or metastatic cARBOplatin and gemcitabine (Day 1 cARBOplatin)

Medium Day 1 Low day 8

September 2020
Bladder/Urothelial locally advanced or metastatic cISplatin and gemcitabine

Medium Day 1 Low day 8

March 2021
Bladder/Urothelial metastatic MVAC (methotrexate vinBLASTine DOXOrubicin cISplatin) Medium September 2022
Bladder/Urothelial metastatic pembrolizumab Low June 2022
Bladder/Urothelial neoadjuvant cISplatin and gemcitabine Medium March 2020
Bladder/Urothelial neoadjuvant ddMVAC (dose dense methotrexate vinBLASTine DOXOrubicin cISplatin) Medium September 2020
Bladder/Urothelial neoadjuvant MVAC (methotrexate vinBLASTine DOXOrubicin cISplatin) Medium March 2021
Bladder/Urothelial small cell cARBOplatin and etoposide Medium September 2022
Bladder/Urothelial small Cell cISplatin and etoposide Medium March 2020

Prostate

Protocol Administration at chemotherapy unit level Review date
Prostate locally advanced or metastatic degarelix Low March 2021
Prostate metastatic castration resistant abiraterone and prednisolone Low June 2022
Prostate metastatic castration sensitive abiraterone and prednisolone
Low June 2022
Prostate metastatic bicalutamide Low March 2020
Prostate metastatic cabazitaxel three weekly and prednisolone Medium September 2020
Prostate metastatic castration sensitive DOCEtaxel three weekly
Medium June 2022
Prostate metastatic cyproterone Low March 2021
Prostate metastatic denosumab Low September 2022
Prostate Metastatic DOCEtaxel three weekly and prednisolone Medium June 2022
Prostate metastatic enzalutamide Low September 2020
Prostate metastatic flutamide Low March 2021
Prostate metastatic goserelin Low September 2022
Prostate metastatic leuprorelin (Eligard) Low March 2020
Prostate metastatic leuprorelin (Lucrin) Low September 2020
Prostate metastatic nilutamide Low September 2022
Prostate metastatic zoledronic acid Low September 2021

Renal

Protocol Administration at chemotherapy unit level Review date
Renal cell metastatic axitinib Low September 2020
Renal cell metastatic cabozantinib Low September 2021
Renal cell metastatic everolimus Low June 2022
Renal cell metastatic ipilimumab and nivolumab (induction)
Medium June 2022
Renal cell metastatic nivolumab (maintenance) following ipilimumab and nivolumab
Low June 2022
Renal cell metastatic nivolumab (flat dosing)
Low June 2022
Renal cell metastatic nivolumab (weight based dosing) Low June 2022
Renal cell metastatic pazopanib Low March 2020
Renal cell metastatic sorafenib Low September 2020
Renal cell metastatic sunitinib Low March 2021
Renal cell metastatic temsirolimus Low September 2022

Testicular

Protocol Administration at chemotherapy unit level Review date
Testicular germ cell advanced or metastatic EP (etoposide cISplatin) Medium March 2020
Testicular germ cell metastatic BEP (bleomycin etoposide cISplatin) Medium September 2020
Testicular germ cell metastatic VIP (etoposide IFOSFamide cISplatin) High March 2021
Testicular germ cell non seminoma adjuvant BEP (bleomycin etoposide cISplatin) Medium June 2022
Testicular germ cell recurrent TIP (PACLItaxel IFOSFamide cISplatin) High March 2020
Testicular germ cell recurrent VeIP (vinBLASTine IFOSFamide cISplatin) Medium / High September 2020
Testicular germ cell seminoma adjuvant cARBOplatin Medium September 2022

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top